Dear Members,
We are pleased to share a significant update regarding the Therapeutic Goods Administration’s (TGA) final decision on the scheduling of amygdalin, hydrocyanic acid, and Wild Cherry Bark in the Poisons Standard.
Following our submission and engagement in the public consultation process, we are pleased to report that the final decision represents a positive step forward. While our initial position was not upheld in the interim decision, we persisted and our advocacy has now resulted in a successful outcome for the industry.
Key Outcomes from the TGA’s Final Decision
🔹 Amygdalin – The previous restriction of 0 mg/kg has been lifted to 10 mg/kg for therapeutic use.
🔹 Hydrocyanic Acid – Now permitted in preparations containing up to 10 mg/kg for therapeutic use.
🔹 Wild Cherry Bark – Now included in Schedule 10, but with exceptions allowing its use when amygdalin and hydrocyanic acid content do not exceed 10 mg/kg.
This decision is a significant improvement from the original proposal and ensures continued access to these important natural medicine ingredients under appropriate regulatory oversight.
What This Means for Our Industry
✅ More appropriate and scientifically justified limits for amygdalin and hydrocyanic acid in complementary medicines.
✅ Greater clarity and regulatory certainty for practitioners using Wild Cherry Bark in formulations.
✅ A strengthened position for future advocacy to ensure natural medicine regulations remain evidence-based.
We would like to thank the ATMS Regulatory Committee for their persistence and expertise, and all members who contributed to the consultation process. Your support continues to strengthen our advocacy for accessible, safe, and effective traditional and complementary medicine. We will continue to represent and advocate for the interests of ATMS members in regulatory matters, academia, and research.
Yours sincerely,
Annie Gibbins
Chief Executive Officer
Australian Traditional Medicine Society
